Our approach to advancing your therapies beyond milestones to transforming lives.
Catalyst is a niche provider of clinical research
services through two established solutions.
Premier provider of multi-therapeutic
resourcing and functional solutions helping to
drive healthcare innovations to patients in need.
A biotech-focused, niche oncology CRO
helping to bring next-generation therapies
to cancer patients in need.
Your success is based on finding real solutions and getting real results.
You deserve a partner who is fully invested in giving you their undivided attention.
Building a culture of customer through collaboration and doing what’s right.
Latest News
Catalyst CEO Nick Dyer Named to 2021 ‘Wilmington Biz 100,’ Described as Community ‘Innovator’
Wilmington Business Publication Highlights Accomplishments of Regional Leaders Wilmington, NC, 8 December 2021 – Catalyst CEO Nick Dyer was recognized as one of Wilmington's top business leaders in 2021 by the WilmingtonBiz publication. Catalyst is headquartered in...
Veteran Biopharma and CRO Executive Marshall Skelton Joins Catalyst in New Role as SVP of People & Culture
The Triangle Business Journal’s ‘Fast 50’ List Salutes High-Growth, Privately Owned Companies Wilmington, NC, 15 November 2021 – Catalyst Clinical Research, a clinical development and global resourcing organization headquartered in Wilmington, NC, recently announced...
For Second Consecutive Year, Catalyst Clinical Research Named One of Fastest Growing Companies in Triangle
The Triangle Business Journal’s ‘Fast 50’ List Salutes High-Growth, Privately Owned Companies Raleigh, NC, 2 November 2021 – Catalyst Clinical Research has ranked number 40 on the Triangle Business Journal’s (TBJ) 2021 list of fastest 50 growing companies for the...
“What makes a difference in this industry is how organizations stand behind their work. Catalyst has been hugely successful because of their integrity and commitment to their customers. No matter how big or small the project, they are your partner and that is why I continue to work with them.”
Mid-size Biopharma